Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. - Wikidata - awgldk - TriplyDB

Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.

Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.

http://www.wikidata.org/entity/Q33559151

about

Clinical Implications of Antiviral Resistance in Influenza Influenza treatment and prophylaxis with neuraminidase inhibitors: a review New small-molecule drug design strategies for fighting resistant influenza A A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice.Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.How I treat influenza in patients with hematologic malignancies.Combinations of L-NG-monomethyl-arginine and oseltamivir against pandemic influenza A virus infections in mice.ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.Combination chemotherapy for influenza.Antiviral strategies for pandemic and seasonal influenza Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.Newer influenza antivirals, biotherapeutics and combinations.Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Animal Models for Influenza Virus Pathogenesis and Transmission.How to approach and treat viral infections in ICU patients Antiviral effect of methylated flavonol isorhamnetin against influenza.Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice Identification of 23-(s)-2-amino-3-phenylpropanoyl-silybin as an antiviral agent for influenza A virus infection in vitro and in vivo Highlights in antiviral drug research: antivirals at the horizon.Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.Antiviral strategies against influenza virus: towards new therapeutic approaches.Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.Antiviral activity of 3,4'-dihydroxyflavone on influenza a virus.Influenza RNA-Dependent RNA Polymerase (RdRp) Inhibitors: Potential New Therapy for Influenza Treatment.Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.Novel oral anti-influenza drug candidate AV5080.The Role of Extracellular Histones in Influenza Virus Pathogenesis.Influenza antivirals and resistance: the next 10 years?The mechanism of resistance to favipiravir in influenza Investigating Different Mechanisms of Action in Combination Therapy for Influenza

P2860

Q26782746-9A6296AB-BED2-4D46-821C-085480C54D62 Q26860032-7A151F69-8858-489A-8518-C8987FD82246 Q28080554-DE67F9A8-3649-445B-BF73-EB3C4D999306 Q28553101-38D3A2ED-FCFC-477B-A22D-1129AEBA244E Q30356466-CEFAD830-18C6-4FC6-ADBF-855866F76C6A Q30359363-306C7B6B-1C61-499C-A4F8-13B82DF39542 Q30364319-AC067C8C-2B05-456A-A9B6-F93D01690EC4 Q30383456-F89A2FE8-6910-4146-A50F-A60E3D32E6D3 Q30401138-543F20C5-B25F-424A-84ED-19B05A415B8C Q30404586-84AAD52C-72FC-45B7-B537-962F12CC7531 Q30408112-300851CA-2E63-4F6C-9CE1-0D231CF674A8 Q30408116-FDB4AD01-67D4-409E-A268-ACCCB4B9B413 Q30414428-4BCF3EA4-A6D1-49B1-89EA-12E7E2161262 Q30456363-CE62F4D6-FA53-42CF-BB05-DDFCFC14BBAA Q34159076-85CE14DB-1C2C-444E-8058-8CB20C5EB442 Q34374652-B06EFC72-8C89-42ED-B301-923E3108BE7E Q34714853-F451D57F-2E2F-4C9D-B9B7-E44ED285B1C6 Q34894660-DBEF6492-2194-4523-B59F-EE7FD091EE8C Q35217208-9D88DB4C-652F-4D47-B163-6D511CC1F8FD Q36301052-E02BCC6A-E65E-43A1-AF44-71B35089B455 Q36607954-23C7878F-5341-4273-A82F-4E0F238402D6 Q36934209-74C38530-FBCD-405A-B3E7-7BFD3E213AC4 Q37124162-AED73ABF-9236-4944-A21B-19B2C5EE5812 Q38007145-47103A4D-58FA-473D-9640-A04CA5949E0F Q38084212-F864E069-D747-4023-AC5D-F960C2D38925 Q38202012-57D8A936-1399-495E-AD30-2500C60C2EF6 Q38694084-42B4AD7E-938E-4D4B-B50C-509870E9BBF6 Q38833628-88FB83C1-4E31-443D-84E0-F317957626C0 Q38990682-A684EB4E-262B-4430-86BF-05B81FF4519C Q39777631-5B4A0383-0C7C-4470-B7A1-0BC2539C07F4 Q40044875-5ABA64E2-3399-46A5-A8A1-E13784B0A9CC Q40743239-AC9D4EC9-4084-4D30-AC77-42EF2366AC7A Q42110040-461D32E1-B45E-4C11-8974-9D68181ADD65 Q42224737-AFFAB27A-8780-42C5-AFDE-6D71C8EB92CD Q45325237-A1293C7B-511F-4891-9361-941CCBF49D48 Q57240687-BD72D3AB-DA55-46CE-B50C-17329A8D3D4D Q57799444-5C6B0357-BDD0-4101-991E-68E3108B1381 Q58573517-5F9DDCD3-0FF8-4D6F-A431-84EE2EA77D93

P2860

Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.

http://www.wikidata.org/entity/Q33559151

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Effects of the combination of ...... za A virus infections in mice.

@ast

Effects of the combination of ...... za A virus infections in mice.

@en

Effects of the combination of favipiravir

@nl

type

label

Effects of the combination of ...... za A virus infections in mice.

@ast

Effects of the combination of ...... za A virus infections in mice.

@en

Effects of the combination of favipiravir

@nl

prefLabel

Effects of the combination of ...... za A virus infections in mice.

@ast

Effects of the combination of ...... za A virus infections in mice.

@en

Effects of the combination of favipiravir

@nl

P1433

Q33559151-5F95D481-8116-4C8C-BB65-51099C39A235

P1476

Q33559151-12B0462F-47E5-450E-93AB-38511A79747F

P2093

Q33559151-21D7E1CF-E32C-408F-BC0D-0A3745BFEA73

Q33559151-6408F502-A52E-45A4-B531-421CF98A6FE3

Q33559151-6A37F9BA-2AF6-42CF-BD6C-D8EF3F85F53D

Q33559151-71DB20A1-975C-45A8-A74A-E3A7DB0F39ED

Q33559151-7E52FA3C-CEFA-44E1-A611-9D0942549A55

P2860

Q33559151-090B7E40-41E6-424D-B9AA-E7802E7BCAFD

Q33559151-0BFB4E80-E8F0-43AD-8216-6092C61F3FEE

Q33559151-2554E592-80F6-451D-963D-D53F01160EDC

Q33559151-26FD34E2-2362-466D-A66D-438D6CE17FB6

Q33559151-450D96B6-7A58-4BBF-8FF0-F9605A586A66

Q33559151-4A31E765-FF32-48B0-B928-8BA4852DD05B

Q33559151-4CBC0EE1-3847-4ABA-9206-EBD82388C4B5

Q33559151-545B9C34-2CD0-445C-9475-F49C1DB0B53B

Q33559151-6031453A-06A1-4AF6-BEF0-A6D22C1D8398

Q33559151-616DFDF0-4833-4B61-8CB5-6703A550522F

P304

Q33559151-45EFFAF9-AA09-4109-88D7-E9EC78466538

P31

Q33559151-20C2E923-B9EC-46D8-9988-D94618FA5ED9

P356

Q33559151-463D947D-CE98-43DA-8B72-A427D84B6AC2

P407

Q33559151-D4704205-9658-4DB2-895D-1120EC14EC95

P433

Q33559151-5EA8CFF0-BB59-49DE-B99C-AB60D5EFBC80

P478

Q33559151-2A7F85FC-940E-4711-B924-2CBBA47856CA

P50

Q33559151-0636DE8B-2783-4F23-85DE-D40BA475FD1A

Q33559151-2CBADEAD-6DBD-4D81-9F4A-0C6506BF22A4

P577

Q33559151-537CB5DF-16DE-4382-AE3B-2413736721CB

P698

Q33559151-279594E2-F02A-4CCC-8B42-6B0A5DA4EF6E

P921

Q33559151-CDB85F0C-0A32-4E95-8205-E0A3B088C1A4

P932

Q33559151-0E178487-6686-430F-8565-4C6D565F1B90

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Effects of the combination of ...... za A virus infections in mice.

@en

P2093

Brett L Hurst

http://www.w3.org/2001/XMLSchema#string

E Bart Tarbet

http://www.w3.org/2001/XMLSchema#string

Kevin W Bailey

http://www.w3.org/2001/XMLSchema#string

Min-Hui Wong

http://www.w3.org/2001/XMLSchema#string

Yousuke Furuta

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia

Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities

Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.

The resurgence of swine-origin influenza A (H1N1).

Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.

Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.

Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent

Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.

P304

126-133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00933-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19901093

http://www.w3.org/2001/XMLSchema#string

P921

P932

2798555

http://www.w3.org/2001/XMLSchema#string